Outset Medical (OM) Registration Filing summary

Company overview and business model

• Pioneers a technology platform, Tablo Hemodialysis System, designed to reduce the cost and complexity of dialysis, FDA-cleared for use from hospital to home.

• Tablo integrates water purification and on-demand dialysate production in a compact console, enabling flexible, mobile dialysis delivery.

• Focuses on simplifying dialysis for providers and improving patient experience, with a proprietary data analytics platform and wireless data transmission.

• Incorporated in Delaware in 2003, rebranded in 2015, with headquarters in San Jose, California.

Financial performance and metrics

• Classified as a smaller reporting company with a public float under $700 million and annual revenue over $100 million.

• As of January 31, 2025, had 53,703,697 shares of common stock and 863,340 shares of Series A Non-Voting Convertible Preferred Stock outstanding.

• As of February 12, 2025, the last reported sale price of common stock was $0.78; aggregate market value held by non-affiliates was $74.0 million.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• May allocate a portion to acquisitions or investments in complementary businesses or products, though no current commitments exist.

• Unused proceeds will be invested in short-term, investment-grade, interest-bearing instruments.